Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

NCT05626400 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

T-cell Acute Lymphoblastic Leukemia/Lymphoma

Interventions

BIOLOGICAL: Senl-T7

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.